palmitoyl-l-carnitine-d3 Palmitoylcarnitine - an overview 8 Stable Isotope Labeled Carnitine

This hypothesis is supported by the appearance of lesions of HFSR specifically in areas chronically exposed to friction and with preexisting hyperkeratosis.20 Recently, the existence of a genetic predisposition to develop sorafenib-induced HFSR has been described in patients with hepatocellular carcinoma.21 Dranitsaris et al.22 developed and validated a predictive model for the onset of HFSR in patients receiving treatment with sorafenib.23,24 The management of HFSR is summarized in Table 3

5. 8-Session Professional Protocol

Krawczyk 2019)

PMID: 33518528

For general context, see peer-reviewed articles in major journals (reading list below)

25 Additionally, there are case reports where valproic acid can precipitate hepatic failure in patients with mitochondrial disorders